457 related articles for article (PubMed ID: 30362224)
1. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC
Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
[TBL] [Abstract][Full Text] [Related]
3. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
Ericsson Å; Fridhammar A
J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636
[No Abstract] [Full Text] [Related]
5. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
6. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
[TBL] [Abstract][Full Text] [Related]
8. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
[No Abstract] [Full Text] [Related]
9. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF
Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
Ishii H; Madin-Warburton M; Strizek A; Thornton-Jones L; Suzuki S
J Med Econ; 2018 May; 21(5):488-496. PubMed ID: 29357718
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m
Dilla T; Alexiou D; Chatzitheofilou I; Ayyub R; Lowin J; Norrbacka K
J Med Econ; 2017 May; 20(5):443-452. PubMed ID: 28008768
[TBL] [Abstract][Full Text] [Related]
13. Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis.
Igarashi A; Hunt B; Wilkinson L; Langer J; Pollock RF
Adv Ther; 2020 Oct; 37(10):4446-4457. PubMed ID: 32870471
[TBL] [Abstract][Full Text] [Related]
14. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
[No Abstract] [Full Text] [Related]
15. The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.
Liebisch-Rey H; Suarez-Chacon AM; Fuentes YV; Blanco J; Kock J; Lechtig-Wassermann S; Bustos RH
F1000Res; 2023; 12():914. PubMed ID: 38125558
[TBL] [Abstract][Full Text] [Related]
16. A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.
Pollock RF; Norrbacka K; Cameron C; Mancillas-Adame L; Jeddi M
J Comp Eff Res; 2019 Mar; 8(4):229-240. PubMed ID: 30644328
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting.
Capehorn M; Hallén N; Baker-Knight J; Glah D; Hunt B
Diabetes Ther; 2021 Feb; 12(2):537-555. PubMed ID: 33423240
[TBL] [Abstract][Full Text] [Related]
18. The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.
Viljoen A; Chubb B; Malkin SJP; Berry S; Hunt B; Bain SC
Eur J Health Econ; 2023 Aug; 24(6):895-907. PubMed ID: 36114904
[TBL] [Abstract][Full Text] [Related]
19. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
20. Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
Evans M; Chubb B; Malkin SJP; Berry S; Lawson J; Hunt B
Diabetes Obes Metab; 2023 Feb; 25(2):491-500. PubMed ID: 36251282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
